Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs).
Cancer of unknown primary (CUP)
Carcinoma
Immunohistochemistry
Malignancies of undefined primary origin (MUO)
Tissue of origin
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
22
07
2022
accepted:
15
10
2022
revised:
10
10
2022
pubmed:
9
11
2022
medline:
25
3
2023
entrez:
8
11
2022
Statut:
ppublish
Résumé
The aim of this study is to envisage a streamlined pathological workup to rule out CUPs in patients presenting with MUOs. Sixty-four MUOs were classified using standard histopathology. Clinical data, immunocytochemical markers, and results of molecular analysis were recorded. MUOs were histologically subdivided in clear-cut carcinomas (40 adenocarcinomas, 11 squamous, and 3 neuroendocrine carcinomas) and unclear-carcinoma features (5 undifferentiated and 5 sarcomatoid tumors). Cytohistology of 7/40 adenocarcinomas suggested an early metastatic cancer per se. In 33/40 adenocarcinomas, CK7/CK20 expression pattern, gender, and metastasis sites influenced tissue-specific marker selection. In 23/40 adenocarcinomas, a "putative-immunophenotype" of tissue of origin addressed clinical-diagnostic examinations, identifying 9 early metastatic cancers. Cell lineage markers were used to confirm squamous and neuroendocrine differentiation. Pan-cytokeratins were used to confirm the epithelial nature of poorly differentiated tumors, followed by tissue and cell lineage markers, which identified one melanoma. In total, 47/64 MUOs (73.4%) were confirmed CUP. Molecular analysis, feasible in 37/47 CUPs (78.7%), had no diagnostic impact. Twenty CUP patients, mainly with squamous carcinomas and adenocarcinomas with putative-gynecologic-immunophenotypes, presented with only lymph node metastases and had longer median time to progression and overall survival (< 0.001), compared with patients with other metastatic patterns. We propose a simplified histology-driven workup which could efficiently rule out CUPs and identify early metastatic cancer.
Identifiants
pubmed: 36346458
doi: 10.1007/s00428-022-03435-z
pii: 10.1007/s00428-022-03435-z
pmc: PMC9640798
doi:
Substances chimiques
Keratins
68238-35-7
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
463-475Subventions
Organisme : AIRC 5x1000
ID : 9970
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Am J Surg. 2018 Nov;216(5):963-968
pubmed: 30143231
Ann Oncol. 2004 Sep;15(9):1377-99
pubmed: 15319245
Oncologist. 2021 Mar;26(3):e394-e402
pubmed: 33219618
Arch Pathol Lab Med. 2014 Dec;138(12):1583-610
pubmed: 25427040
Brief Bioinform. 2021 Mar 22;22(2):2106-2118
pubmed: 32266390
Ann Oncol. 2012 Jul;23(7):1854-63
pubmed: 22115926
BMC Cancer. 2020 Jul 9;20(1):639
pubmed: 32646508
Trends Cancer. 2021 May;7(5):465-477
pubmed: 33516660
Nat Commun. 2021 May 3;12(1):2498
pubmed: 33941777
Adv Anat Pathol. 2020 May;27(3):114-163
pubmed: 32205473
Oncologist. 2021 May;26(5):e769-e779
pubmed: 33687747
Cureus. 2019 Sep 2;11(9):e5552
pubmed: 31695975
Front Oncol. 2020 Jan 17;9:1546
pubmed: 32010631
EMBO Mol Med. 2020 Jul 7;12(7):e11756
pubmed: 32511869
Eur J Cancer. 2021 Nov;157:179-189
pubmed: 34521064
Ann Oncol. 2015 Sep;26 Suppl 5:v133-8
pubmed: 26314775
Semin Diagn Pathol. 2018 May;35(3):199-206
pubmed: 29203116
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
J Clin Oncol. 2010 Jul 10;28(20):3388-404
pubmed: 20530278
Lancet Oncol. 2016 Oct;17(10):1386-1395
pubmed: 27575023
Cancers (Basel). 2021 Jan 25;13(3):
pubmed: 33504059